Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.59 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | IL6ST | P40189 | 3/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 4/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 5/20 | 0.39 |
| ▸ | STAT3 | P40763 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20825575 | 1.00 | PPARA (0.59) | PPARAPPARGIL6STNAAAACE | |
| SCHEMBL22552723 | 1.00 | PPARA (0.59) | PPARAPPARGIL6STNAAAACE | |
| SCHEMBL20820036 | 1.00 | PPARA (0.59) | PPARAPPARGIL6STNAAAACE | |
| SCHEMBL28900400 | 1.00 | PPARA (0.59) | PPARAPPARGIL6STNAAAACE | |
| SCHEMBL28900402 | 1.00 | PPARA (0.59) | PPARAPPARGIL6STNAAAACE | |
| SCHEMBL28582204 | 0.99 | PPARA (0.58) | PPARAPPARGIL6STNAAAACE | |
| SCHEMBL28582203 | 0.99 | PPARA (0.58) | PPARAPPARGIL6STNAAAACE | |
| SCHEMBL28708853 | 0.99 | PPARA (0.58) | PPARAPPARGIL6STNAAAACE | |
| SCHEMBL13295722 | 0.99 | PPARA (0.58) | PPARAPPARGIL6STNAAAACE | |
| SCHEMBL28708851 | 0.99 | PPARA (0.58) | PPARAPPARGIL6STNAAAACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3681875-B1 | CYCLIC PEPTIDE ANTIBIOTICS | HOFFMANN LA ROCHE (CH) | 2026-01-14 | — | — | EP | disclosed |
| CN-111148739-B | Cyclic peptide antibiotics | 豪夫迈·罗氏有限公司 | 2025-06-03 | — | — | CN | disclosed |
| US-11279735-B2 | Cyclic peptide antibiotics | GENENTECH, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-20200331968-A1 | CYCLIC PEPTIDE ANTIBIOTICS | GENENTECH, INC. (US) | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331968-A1 | CYCLIC PEPTIDE ANTIBIOTICS | NPPA, LNPEP, CLPP | PPARA 455/4885PPARG 1675/4885IL6ST 2327/4885 |
| US-11279735-B2 | Cyclic peptide antibiotics | NPPA, LNPEP, CLPP | PPARA 455/4885PPARG 1675/4885IL6ST 2327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.